Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)
The purpose of this study is to test the effectiveness and implementation process of a culturally and contextually tailored telehealth-based community health worker (CHW) led coaching intervention for hypertension control among South Asian patients with co-morbid Diabetes Mellitus type II (DMII) and hypertension. The primary aims are to test the effectiveness of a CHW-led telehealth intervention compared to usual care, and using Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) and Consolidated Framework for Implementation Research (CFIR), examine the reach, adoption, fidelity, and maintenance of the intervention within clinical and community settings.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University
-
-
New York
-
New York, New York, Estados Unidos, 10016
- NYU Langone Health
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- identified as of South Asian ethnicity
- at least 21 years of age
- a diagnosis of diabetes
- a diagnosis of hypertension
- an uncontrolled BP reading (>130/80mmHg) in the last 6 months
Exclusion Criteria:
- Under the age of 21
- Women who are pregnant at the time of screening
- Type 1 diabetes or diabetes secondary to other conditions (e.g., steroid-induced, pancreatic insufficiency, or chemotherapy-induced)
- Inability to perform unsupervised physical activity
- Malignancy or life-threatening illness with life expectancy of <5 years
- Diagnosed cognitive deficits or limited decision-making capacity
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Community Health Workers (CHW) treatment group
There is a 6-month intervention period immediately following recruitment. Participants enrolled in the intervention will complete 5 educational sessions and attend 2 one-on-one virtual meetings. |
Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc. |
|
Comparador Ativo: Control group
The control participants will complete only the first educational session. The control arm will receive usual care from their primary care physician (PCP) during the first 12 months of data collection. After 12 months they will be invited to attend remaining group sessions. |
Participants will attend only the first group-based health education session on hypertension and diabetes management. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent of participants achieving BP control, defined as <130/80 mmHg
Prazo: Month 6
|
The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) at six months. |
Month 6
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent of participants achieving BP control, defined as <130/80 mmHg
Prazo: Month 12
|
The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) at twelve months. |
Month 12
|
|
Change from Baseline in hemoglobin A1c (HbA1c) levels at Month 6
Prazo: Baseline, Month 6
|
Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 6
|
|
Change from Baseline in HbA1c levels at Month 12
Prazo: Baseline, Month 12
|
Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 12
|
|
Change from Baseline in Body mass index (BMI) at Month 6
Prazo: Baseline, Month 6
|
Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 6
|
|
Change from Baseline in BMI at Month 12
Prazo: Baseline, Month 12
|
Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 12
|
|
Change from Baseline in Systolic blood pressure (SBP) at Month 6
Prazo: Baseline, Month 6
|
Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 6
|
|
Change from Baseline in SBP at Month 12
Prazo: Baseline, Month 12
|
Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 12
|
|
Change from Baseline in Diastolic blood pressure (DBP) at Month 6
Prazo: Baseline, Month 6
|
Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 6
|
|
Change from Baseline in DBP at Month 12
Prazo: Baseline, Month 12
|
Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR. |
Baseline, Month 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nadia Islam, PhD, NYU Langone Health
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 19-01192-2
- 5R01MD018528-02 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: laura.wyatt@nyulangone.org . The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Prazo de Compartilhamento de IPD
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Critérios de acesso de compartilhamento IPD
The investigator who proposed to use the data will be provided access upon reasonable request. Requests should be directed to laura.wyatt@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .